In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on Neuspera’s innovative integrated sacral ...

A panelist discusses how different abiraterone formulations require specific steroid combinations—prednisone with traditional abiraterone and prednisolone with microformulation—and the importance of ...

In this landmark episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with one of the world’s foremost experts in sexual medicine, John P. Mulhall, MD, of Memorial Sloan Kettering Cancer ...

CMS issued a permanent HCPCS code for Gozellix, effective October 1, 2025, aiding billing and reimbursement processes. Gozellix, approved in March 2025, targets prostate cancer patients with suspected ...

Justin Dubin, MD, discussed how patients' growing trust in digital tools could be leveraged to support lifestyle changes and improve health outcomes.

A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.

On Saturday, August 2, 2025, Northwestern University is hosting a course titled "Advances in Genitourinary Robotic Reconstruction." In this video, Ziho Lee, MD, the course director and assistant ...

Key Takeaways Hamlet BioPharma is preparing to initiate a phase 3 trial of Alpha1H for NMIBC, following a successful FDA meeting. Alpha1H received fast track designation, allowing for accelerated ...

On June 18, 2025, the FDA granted clearance to Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for the treatment of patients with urinary urge incontinence. 1 In this video, Andrea ...

Millennial urologists appear to have developed strong opinions on health policy as reflected by their recent social media activity, observes urologist Alan L. Kaplan, MD.

The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

An expert would summarize that bladder cancer management is evolving from traditional radical surgery toward more personalized, less invasive approaches—highlighting promising therapies like Terra-002 ...